Research

What a trial of semaglutide in children 6 to under 12 actually found

Medically reviewed by Dr. Patrick Taylor, MDPublished November 16, 2026

A phase 3 randomized trial published in The New England Journal of Medicine tested once-weekly semaglutide against placebo in young children with obesity over 104 weeks. Here is what it reported and what it does not settle for anyone weighing physician-prescribed care.

This is a summary of a single study. It looked at children 6 to under 12 years of age with obesity, not adults. If you are an adult considering care, keep that difference in mind as you read, because the trial does not speak to your situation directly.

The study, published in The New England Journal of Medicine and funded by Novo Nordisk, was a phase 3, double-blind, randomized, placebo-controlled trial. Participants were human children, not animals or cells. The trial is registered as STEP Young, ClinicalTrials.gov number NCT05726227.

What the researchers studied

Researchers enrolled 167 children and randomly assigned them in a 2-to-1 ratio: 112 received once-weekly subcutaneous semaglutide and 55 received placebo. Treatment ran for 104 weeks, followed by a 7-week period off the drug. Both groups also received counseling for lifestyle modification, so neither group was left with medication or placebo alone.

The main question, the primary end point, was the percent change in body-mass index from the start to week 68. BMI is weight in kilograms divided by height in meters squared. A second, confirmatory measure was whether children moved to a lower BMI category by week 68.

What the trial reported

At week 68, mean BMI changed by -13.5% with semaglutide and +2.7% with placebo, an estimated between-group difference of -16.2 percentage points (95% CI, -19.4 to -12.9; P<0.001). At week 104, the figures were -9.4% with semaglutide and +8.4% with placebo.

On the category measure, 79% of children in the semaglutide group showed a reduction in BMI category at week 68, compared with 23% in the placebo group. In 38% of semaglutide participants, BMI fell below the threshold for obesity, the 95th percentile for age and sex, versus 2% with placebo.

On safety, adverse events occurred in 96% of the semaglutide group and 93% of the placebo group. Gastrointestinal adverse events were the most common, happened more often with semaglutide, and led one participant in the semaglutide group to stop treatment.

What it does and does not establish

The trial establishes that, over 68 weeks and alongside lifestyle counseling, young children on semaglutide had a significantly greater average reduction in BMI than those on placebo. That is a finding about a group average under study conditions, not a prediction for any one child or adult.

It does not establish results for adults, and it does not tell you what any individual should expect. Outcomes vary by person. The study also does not provide a dose you can act on; in real care, a physician determines that after a medical intake. This summary is general information, not medical advice.

One honest limitation

The study was relatively small, with 167 children, and the group that stayed on treatment longest was smaller still. It was funded by the drug's manufacturer. Longer-term safety and what happens after stopping are not fully answered by a single trial of this size and length, which is why ongoing clinical judgment matters.

Semaglutide for young children is not what this reflects for most readers. Live Vital's care is physician-prescribed for eligible adults, and eligibility is never assumed.

If you are an adult curious about GLP-1 care, semaglutide through Live Vital is physician-prescribed and requires a medical intake and physician approval. You can start that review at /get-started or ask questions first at a free consult at /consult. A prescription is never guaranteed.

This article is general information, not medical advice. Live Vital treatments are physician-prescribed and require a medical intake and physician approval. Outcomes vary by individual. Talk to a licensed clinician about what is right for you.

Related treatments